Please join us on Wednesday, March 25 at 11 a.m. EST for a presentation by Dr. Borje Darpo, where he will discuss how the Early Precision QT (EPQT) methodology allows ECGs collected and analyzed during routine early-phase studies to reliably provide cardiac safety information historically derived from large, dedicated high-cost TQT studies. By implementing EPQT into a Phase I study, Sponsors can obtain precise, actionable data earlier in the drug development process, providing a more cost-effective path for characterizing QT effect and potentially allowing sponsors to qualify for a TQT waiver.
Understand differentiators of the EPQT methodology, and get some background to help achieve a better understanding of this unique offering.
Also, see what else is new in the space, including JTPeak and updated FDA Blood Pressure guidance.
As an ERT Certified Site, you and your team are receiving this invitation to an exclusive webinar series. We appreciate the work Certified Sites do to deliver Sponsors superior, highly-precise ECG data. Please share this with any members of your team, including clinicians, operations, business development, proposals, procurement and contracts. Also, we’d love to hear your ideas for future webinars, so please feel free to share!